LMR Partners LLP Purchases Shares of 64,817 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

LMR Partners LLP purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 64,817 shares of the company’s stock, valued at approximately $1,429,000.

Other institutional investors have also made changes to their positions in the company. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $44,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $66,000. IFP Advisors Inc boosted its stake in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after purchasing an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC boosted its stake in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock valued at $96,000 after purchasing an additional 949 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TEVA has been the subject of several recent research reports. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Finally, Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $24.43.

Teva Pharmaceutical Industries Stock Down 2.7%

Shares of Teva Pharmaceutical Industries stock opened at $17.48 on Wednesday. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a 50 day moving average of $15.22 and a 200 day moving average of $17.44. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company has a market capitalization of $19.82 billion, a P/E ratio of -12.06, a P/E/G ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. As a group, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.